Acetylcholine receptors in small cell carcinomas.

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Small cell lung carcinoma (SCC) is a neuroendocrine tumor.
• Muscarinic (mAChR) and nicotinic (nAChR) acetylcholine receptors are key components of the nervous system.
• SCC cells have been investigated for neural markers.

Purpose of the Study:

• To determine the presence and characteristics of mAChR and nAChR in human SCC.
• To investigate whether mAChR expression in SCC is linked to neurological paraneoplastic syndromes.

Main Methods:

• Radioligand binding assays were used to measure specific binding of (-)[3H]quinuclidinyl benzilate ([3H]QNB) for mAChR and 125I-alpha-bungarotoxin for nAChR.
• Saturation isotherms and competition studies were performed to characterize receptor binding.
• The effect of 5'-guanylyl imidodiphosphate on mAChR binding was assessed.

Main Results:

• All five SCC samples studied showed specific binding of [3H]QNB, indicating the presence of mAChR.
• No specific binding of 125I-alpha-bungarotoxin was detected, suggesting the absence of nAChR.
• Pharmacological profiling confirmed the presence of mAChR, likely of the M2 subclass.
• Guanine nucleotide analogue affected mAChR affinity, consistent with G-protein coupling.

Conclusions:

• SCC expresses mAChR, specifically the M2 subclass, which can serve as a neural differentiation marker.
• The expression of mAChR in SCC is not limited to patients with paraneoplastic syndromes affecting cholinergic neurons.
• The absence of nAChR in SCC was also demonstrated.